Business Context and Reporting Period
Anika Therapeutics, Inc. (Nasdaq: ANIK) filed a Form 8-K on July 10, 2026, reporting the entry into a material definitive agreement. The company is incorporated in Delaware and maintains its principal executive offices in Bedford, Massachusetts.
Key Financial Metrics and Debt Structure
The filing details a Fifth Amendment to the company's Credit Agreement with Bank of America, N.A., effective July 10, 2026. Key terms include:
- Facility Size: A senior revolving line of credit of $50.0 million.
- Expansion Option: Subject to conditions and lender approval, the company may request an additional $50.0 million, bringing the maximum aggregate commitment to $100.0 million.
- Maturity Date: July 10, 2031.
- Interest Rate: SOFR plus a margin ranging from 0.25% to 1.25%, determined by the consolidated leverage ratio.
- Commitment Fee: 0.20% to 0.30% per annum on the unused portion of the facility, payable quarterly.
- Collateral: Lenders hold a first priority lien on substantially all assets, excluding certain intangible assets.
The filing does not provide specific values for revenue, profit, cash flow, or current liquidity positions.
Material Changes and Covenants
The amendment extends the maturity of the credit facility to 2031 and establishes new pricing tiers based on leverage. The agreement includes customary affirmative and negative covenants, specifically:
- Maximum leverage ratio and interest coverage ratio requirements.
- Restrictions on incurring additional liens and indebtedness.
- Limitations on merger, acquisition, and disposition transactions.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the amended credit terms. The primary risk associated with this filing is the potential for an event of default if the company fails to meet the specified financial covenants regarding leverage and interest coverage. Loan origination costs will be amortized over the five-year term of the agreement.
Investor Verification Checklist
- Verify the company's current consolidated leverage ratio to determine the applicable interest rate margin and commitment fee.
- Review the full text of the Fifth Amendment (Exhibit 10.1) for specific definitions of the financial covenants.
- Assess the company's ability to meet the interest coverage ratio requirements under current market conditions.
- Confirm whether the company intends to exercise the option to increase the credit facility to $100.0 million.